东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02348 东瑞制药

收市竞价 10-07 16:09:44

0.960

-0.005

-0.52%

最高0.965	最低0.960	成交量21.60万
今开0.960	昨收0.965	日振幅0.52%
总市值14.47亿	流通市值14.47亿	总股本15.07亿
成交额20.77万	换手率0.01%	流通股本15.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02348","market":"HK","secType":"STK","nameCN":"东瑞制药","latestPrice":0.96,"timestamp":1791358243474,"preClose":0.965,"halted":0,"volume":216000,"delay":0,"changeRate":-0.005181347150259072,"floatShares":1507000000,"shares":1507000000,"eps":0.1638579556601923,"marketStatus":"收市竞价","change":-0.005,"latestTime":"10-07 16:09:44","open":0.96,"high":0.965,"low":0.96,"amount":207660,"amplitude":0.005181,"askPrice":0.96,"askSize":64000,"bidPrice":0.955,"bidSize":60000,"shortable":0,"etf":0,"ttmEps":0.1783804521875613,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791360600000},"marketStatusCode":4,"adr":0,"listingDate":1057852800000,"exchange":"SEHK","adjPreClose":0.965,"dividendRate":0.065625,"openAndCloseTimeList":[[1791336600000,1791345600000],[1791349200000,1791360000000]],"volumeRatio":0.885246,"lotSize":4000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02348","defaultTab":"news","newsList":[{"id":"1121902601","title":"东瑞制药2026年9月股份变动月报表：股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1121902601","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121902601?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:26","pubTimestamp":1791195986,"startTime":"0","endTime":"0","summary":"东瑞制药(控股)有限公司于2026年10月5日发布的公告显示，截至2026年9月30日，公司注册股本为20,000,000,000股普通股，每股面值0.05港元，总额仍为1,000,000,000港元，与上月保持一致。公告亦显示当月并无新增发行、回购、注销或库藏股变动，公司股本结构维持稳定。关于股份期权情况，2013年6月21日生效的“2013购股权计划”在本月内累计结存的股份期权为4,680,000份，较上月底无变化；本月并无因行使期权而新增股份发行。公告由公司秘书彭洁玲签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119267317","title":"东瑞制药：李其玲增持，好仓比例升至47.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119267317","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119267317?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:24","pubTimestamp":1790933058,"startTime":"0","endTime":"0","summary":"李其玲于2026年9月30日在联交所场内以每股均价0.973港元买入东瑞制药股份17.20万股，涉资约16.74万港元，属场内主动交易，即在二级市场直接买卖股份。李其玲此次增持前持有东瑞制药好仓7.12亿股，占比47.22%；增持后持股量为7.12亿股，好仓比例升至47.24%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179179612","title":"东瑞制药：熊融礼增持，好仓比例升至40.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179179612","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179179612?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:23","pubTimestamp":1790933028,"startTime":"0","endTime":"0","summary":"熊融礼于2026年9月30日在联交所场内以每股均价0.973港元买入东瑞制药股份17.20万股，涉资约16.74万港元，属场内主动交易，即在二级市场直接买卖股份。熊融礼此次增持前持有东瑞制药好仓6.06亿股，占比40.20%；增持后持股量为6.06亿股，好仓比例升至40.21%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129715491","title":"东瑞制药：李其玲增持，好仓比例升至47.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129715491","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129715491?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:41","pubTimestamp":1790761313,"startTime":"0","endTime":"0","summary":"李其玲于2026年9月28日在联交所场内以每股均价0.9750港元买入东瑞制药股份9.60万股，涉资约9.36万港元，属场内主动交易，即在二级市场直接买卖股份。李其玲此次增持前持有东瑞制药好仓7.12亿股，占比47.21%；增持后持股量为7.12亿股，好仓比例升至47.22%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169678526","title":"东瑞制药：熊融礼增持，好仓比例升至40.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169678526","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169678526?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:42","pubTimestamp":1790242949,"startTime":"0","endTime":"0","summary":"熊融礼于2026年9月23日在联交所场内以每股均价0.985港元买入东瑞制药7.60万股，涉资约7.49万港元，属场内主动交易，即在二级市场直接买卖股份。熊融礼此次增持前持有东瑞制药好仓6.06亿，占比40.18%；增持后持股量为6.06亿，好仓比例升至40.19%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113616063","title":"东瑞制药：李其玲增持，好仓比例升至47.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113616063","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113616063?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:23","pubTimestamp":1790241791,"startTime":"0","endTime":"0","summary":"李其玲于2026年9月22日在联交所场内以每股均价0.975港元买入东瑞制药9.20万股，涉资约8.97万港元，属场内主动交易，即在二级市场直接买卖股份。李其玲此次增持前持有东瑞制药好仓7.11亿股，占比47.20%；增持后持股量为7.11亿股，好仓比例升至47.21%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171887526","title":"东瑞制药：熊融礼增持，好仓比例升至40.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171887526","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171887526?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:32","pubTimestamp":1790069579,"startTime":"0","endTime":"0","summary":"熊融礼于2026年9月21日在联交所场内以每股均价0.9788港元买入东瑞制药（02348）股份6.40万股，涉资约6.26万港元，属场内主动交易，即在二级市场直接买卖股份。熊融礼此次增持前持有东瑞制药好仓6.05亿股，占比40.17%；增持后持股量为6.06亿股，好仓比例升至40.18%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105431817","title":"东瑞制药2026年中期财报：营收5.46亿元，净利润1.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105431817","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105431817?lang=zh_cn&edition=full","pubTime":"2026-09-17 13:33","pubTimestamp":1789623199,"startTime":"0","endTime":"0","summary":"东瑞制药在其最新公布的2026年中期业绩报告中显示，报告期内公司实现营收5.46亿元，同比下降13.4%。同期净利润为1.23亿元，同比上升18.0%。毛利率达51.8%，较上年同期提升2.0个百分点；期内经营活动产生的现金流净额为1.90亿元，相较上年同期的2.02亿元略有回落。成本结构方面，销售费用约3,940万元，同比下降30.7%；管理费用约6,211万元，同比减少8.0%；研发投入合计约3,503万元，占营收比重为6.4%，同比减少38.4%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东瑞制药2026年中期财报：营收5.46亿元，净利润1.23亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172772167","title":"东瑞制药：熊融礼增持，好仓比例升至40.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172772167","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172772167?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:41","pubTimestamp":1788774108,"startTime":"0","endTime":"0","summary":"熊融礼于2026年9月4日以每股均价0.99港元买入东瑞制药股份6.00万股，涉资约5.94万港元。熊融礼此次增持前持有东瑞制药好仓6.05亿股，占比40.16%；增持后持股量为6.05亿股，好仓比例升至40.17%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177732974","title":"东瑞制药：李其玲增持，好仓比例升至47.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177732974","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177732974?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:11","pubTimestamp":1788772262,"startTime":"0","endTime":"0","summary":"根据披露，李其玲于2026年9月3日以每股均价1.0000港元买入东瑞制药股份10.40万股，涉资约10.40万港元。李其玲此次增持前持有东瑞制药好仓7.11亿股，占比47.18%；增持后持股量为7.11亿股，好仓比例升至47.19%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127907903","title":"东瑞制药2026年8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127907903","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127907903?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:16","pubTimestamp":1788344174,"startTime":"0","endTime":"0","summary":"东瑞制药于2026年9月2日发布2026年8月股份变动月报表。报告显示，截至2026年8月31日，公司法定/注册股本与上月底保持一致，注册总股本维持为20,000,000,000股，每股面值为0.05港元，合计约10亿港元。公司确认已满足适用的公众持股量要求，报告期内并无股份发行、购回或注销事项。2023年购股权计划保持22,900,000份股份期权，报告期内有关该计划的持股数量未发生变化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662603064","title":"东瑞制药：10月9日将派发股息0.015港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662603064","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662603064?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:30","pubTimestamp":1787913000,"startTime":"0","endTime":"0","summary":"南财智讯8月28日电，东瑞制药（02348.HK）公告，公司将于2026年10月9日派发截至2026年6月30日止六个月的中期股息，每股派发0.015港元。除净日为2026年9月22日，为符合获派股息资格，股份过户文件须于2026年9月23日16:30前递交；公司将于2026年9月24日至9月25日暂停办理股份过户登记手续，记录日期为2026年9月25日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283858379945.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283858379945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","VIG","BK4588","EWH","BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196050829","title":"东瑞制药2026年中期营收5.46亿元同比下降13.4%，净利润1.23亿元同比增长18.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196050829","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196050829?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:25","pubTimestamp":1787912709,"startTime":"0","endTime":"0","summary":"东瑞制药发布截至2026年6月30日止六个月的财报。期内实现营收5.46亿元，同比下降13.4%。同期净利润为1.23亿元，同比增长18.0%。毛利为2.83亿元，同比减少9.9%，毛利率从上年同期的49.8%提升至51.8%。期间销售费用与管理费用均有所下降，研发投入约0.35亿元，占营收比重6.4%。经营活动现金流净流入约1.90亿元，相比去年同期的2.02亿元略有下滑。成本结构方面，销售及分销费约0.39亿元，同比减少30.6%；行政费用约0.62亿元，同比减少8.0%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东瑞制药2026年中期营收5.46亿元同比下降13.4%，净利润1.23亿元同比增长18.0%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181244902","title":"东瑞制药宣布派发中期股息 每股0.015港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181244902","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181244902?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:19","pubTimestamp":1787912349,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）正式宣告，针对截至2026年12月31日止财政年度，公司将派发中期股息，每股金额为0.015港元。这一决定标志着公司在当前财年中的股东回报计划迈出关键一步。值得注意的是，此次派息方案展现了管理层对业绩稳定性的信心，同时也为投资者提供了切实的现金收益。在东瑞制药的财务规划中，此举无疑是对股东长期支持的一种积极回应。每股0.015港元的中期红利，虽数额不大，却透露出公司对资本配置的审慎态度与持续分红的承诺。此举或将进一步巩固市场对这家制药企业未来盈利前景的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112622","title":"东瑞制药(02348.HK)拟8月28日举行董事会会议审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112622","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659112622?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:57","pubTimestamp":1786697824,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨东瑞制药(02348.HK)宣布，公司将于2026年8月28日(星期五)举行董事会会议，藉以(其中包括)考虑及批准公司及其附属公司截至2026年6月30日止六个月之中期业绩及其刊发，以及考虑派付中期股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260814/32335295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124318854","title":"东瑞制药（02348）拟于2026年8月28日审议中期业绩及股息方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1124318854","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124318854?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:37","pubTimestamp":1786696650,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司（股票代码：02348）8月14日公告，公司董事会已排定于2026年8月28日（星期五）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及相关公告，并同步讨论及考虑是否派发中期股息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166984249","title":"东瑞制药更新2026年7月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1166984249","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166984249?lang=zh_cn&edition=full","pubTime":"2026-08-05 15:11","pubTimestamp":1785913904,"startTime":"0","endTime":"0","summary":"东瑞制药(控股)有限公司于2026年8月5日发布截至2026年7月31日的股份变动月报表。报告显示，公司在报告期内已发行股本由上月底的1,506,391,000股增加至1,507,025,000股，增幅为634,000股。公司确认其公众持股量继续符合香港联交所规定的25%最低要求。公司注册股本维持在10亿港元不变，股份面值为每股0.05港元。2023购股权计划自5月25日采纳后，本月内授出10,000,000股期权并有2,500,000股失效，期末结存数量为22,900,000股期权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648663125","title":"东瑞制药(02348)授出合共1000万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2648663125","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648663125?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:04","pubTimestamp":1783076698,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东瑞制药(02348)发布公告，于2026年7月3日，公司根据2023购股权计划向集团若干合资格雇员授出合共1000万份购股权以认购股份，惟须待承授人接纳方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153743637","title":"东瑞制药更新2026年6月股份变动月报表，股本增加至1,506,391,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1153743637","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153743637?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:44","pubTimestamp":1783075477,"startTime":"0","endTime":"0","summary":"东瑞制药(控股)有限公司于2026年7月3日发布截至2026年6月30日的股份变动月报表。公告显示，公司法定注册股本保持不变，仍为20,000,000,000股普通股，面值每股0.05港元，合计10亿港元。月报数据显示，公司已发行的普通股由2026年5月底的1,505,691,000股增至2026年6月底的1,506,391,000股，增加700,000股。2023购股权计划于本月内有600,000股期权失效，但无新股发行、购回或注销动作。本次公告由公司秘书彭洁玲签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208403","title":"东瑞制药：拟向上海建信东瑞生物医药创业投资基金出资1亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208403","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644208403?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:44","pubTimestamp":1781793840,"startTime":"0","endTime":"0","summary":"南财智讯6月18日电，东瑞制药（02348.HK）发布须予披露交易公告，于2026年6月18日，公司全资附属公司苏州东瑞作为有限合伙人，与中建信（有限合伙人）及上海建信（普通合伙人）订立有限合伙协议，拟共同设立上海建信东瑞生物医药创业投资基金合伙企业（有限合伙），苏州东瑞承诺出资最高达人民币100000000元，占合伙企业拟定资本的50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606183776507447.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606183776507447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399441","BK1191","161726","BK4581","BK4588","BK4585","02348","XBI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dawnrays.com","stockEarnings":[{"period":"1week","weight":-0.0153},{"period":"1month","weight":-0.0052},{"period":"3month","weight":-0.0203},{"period":"6month","weight":-0.1015},{"period":"1year","weight":-0.1601},{"period":"ytd","weight":-0.1601}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":-0.0534},{"period":"3month","weight":0.0034},{"period":"6month","weight":-0.0572},{"period":"1year","weight":-0.0993},{"period":"ytd","weight":-0.0527}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东瑞制药（控股）有限公司是一家主要从事非专利药物的开发、制造及销售业务的投资控股公司。该公司通过两个部门运营业务。成药分部从事制造及销售成药。中间体及原料药分部从事制造及销售中间体及原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":0.000418},{"month":2,"riseRate":0.478261,"avgChangeRate":-0.004351},{"month":3,"riseRate":0.478261,"avgChangeRate":0.01752},{"month":4,"riseRate":0.695652,"avgChangeRate":0.037866},{"month":5,"riseRate":0.478261,"avgChangeRate":0.017383},{"month":6,"riseRate":0.565217,"avgChangeRate":0.00718},{"month":7,"riseRate":0.565217,"avgChangeRate":0.018527},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.018216},{"month":9,"riseRate":0.458333,"avgChangeRate":0.020152},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.002049},{"month":11,"riseRate":0.565217,"avgChangeRate":0.036297},{"month":12,"riseRate":0.565217,"avgChangeRate":0.012921}],"exchange":"SEHK","name":"东瑞制药","nameEN":"DAWNRAYS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东瑞制药(02348)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东瑞制药,02348,东瑞制药股票,东瑞制药股票老虎,东瑞制药股票老虎国际,东瑞制药行情,东瑞制药股票行情,东瑞制药股价,东瑞制药股市,东瑞制药股票价格,东瑞制药股票交易,东瑞制药股票购买,东瑞制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东瑞制药(02348)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}